📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-24 17:32
6 analysed today
FollowTelegram
6
Today
149,957
All-time analysed
42,989
Positive
6,669
Negative
91,589
Neutral
8,642
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Choksi Laboratories Calls EGM to Issue ₹6.20 Cr Convertible Warrants to Promoters at ₹177/Share
Choksi Laboratories has convened an Extra-Ordinary General Meeting (EGM) on October 17, 2026, to approve the preferential issuance of up to 3,50,000 convertible warrants at ₹177 each to promoters, raising up to ₹6,19,50,000. The proposed issuance represents approximately 4.2% of the company's current ₹146 Cr market cap. Upon full conversion within 18 months, promoter shareholding will increase from 31.48% (21,92,754 shares) to 34.76% (25,42,754 shares). The warrant issue price of ₹177 is at a discount to the current market price of ₹209.9.
Confidence: HIGH
What changedChoksi Laboratories issued an EGM notice to seek shareholder approval for raising ₹6.20 Cr via convertible warrants issued to promoters.
Why it mattersThe fundraise injects fresh equity capital equivalent to ~24% of existing net worth (₹26 Cr) and increases promoter skin-in-the-game by 3.28% in voting rights.
Total fundraise amount: Rs. 6,19,50,000/-Issue price per warrant: Rs. 177/-Number of warrants: 3,50,000Fundraise vs Market Cap: ~4.2%Promoter post-dilution stake: 34.76%
📅 Short termShareholders will vote via remote e-voting (Oct 14-16) ahead of the Oct 17 EGM. The pricing at ₹177 offers promoter alignment, though at a discount to recent trading levels of ~₹210.
📈 Long termStrengthens equity base (from ₹26 Cr) and provides cash to support laboratory expansion or pare down existing debt of ₹31 Cr.
⚠ Risk flags
- Issue price (₹177) is at a discount to the prevailing market price (₹209.9)
- Dilution of non-promoter public shareholding from 68.52% to 65.24%
Key Highlights
Preferential allotment of up to 3,50,000 convertible warrants at an issue price of ₹177 per warrant (including ₹167 premium)
Aggregate fundraise of up to ₹6,19,50,000 (~₹6.20 Cr) for cash consideration
Promoter holding to increase from 31.48% to 34.76% on fully diluted equity share capital post-conversion
E-voting runs from October 14 to October 16, 2026, with the EGM scheduled for October 17, 2026
👀 What to Watch
Track shareholder voting results on or before October 19, 2026, and in-principle approval from BSE. Monitor subsequent warrant subscription and deployment of proceeds toward business operations or debt reduction.
Choksi Laboratories approves ₹6.20 Cr preferential warrant issue to promoters at ₹177/share
Choksi Laboratories' board has approved the issuance of up to 3,50,000 convertible equity warrants on a preferential basis to promoters at an issue price of ₹177 per warrant, aggregating to ₹6.20 crore. The fundraise equals ~4.2% of the company's current market cap of ₹146 crore and will inject fresh equity into the balance sheet. An upfront payment of 25% is payable on subscription, with the remaining 75% payable on conversion within 18 months. The issuance is subject to shareholder approval at an Extra-Ordinary General Meeting scheduled for October 17, 2026.
Confidence: HIGH
What changedThe Board approved the issuance of 3.5 lakh convertible warrants exclusively to promoters, aggregating ₹6.20 crore.
Why it mattersIncreases promoter skin-in-the-game and injects equity capital into a small-cap firm with ₹31 Cr debt and a D/E of 1.20.
Issue size: Rs. 6,19,50,000Number of warrants: 3,50,000Issue price per warrant: Rs. 177Issue size vs Market cap: ~4.2%Issue size vs Debt: ~20.0%
📅 Short termMarket may view promoter capital infusion favorably as a sign of confidence, though price per warrant (₹177) is below the current market price of ₹209.9.
📈 Long termIf funds are deployed toward reducing the ₹31 Cr debt burden, interest expenses could fall, improving the current modest net profit margins.
⚠ Risk flags
- Equity dilution of minority shareholders as promoter stake expands
- Issue price (₹177) is at a discount to the current market price (₹209.9)
Key Highlights
Board approved issuance of up to 3,50,000 convertible warrants at ₹177 per warrant, raising up to ₹6,19,50,000
Allotment is entirely to 3 promoter individuals: Sunil Choksi (2,00,000 warrants), Himika Choksi (1,00,000), and Stela Choksi (50,000)
Payment structured as 25% on subscription and allotment, with balance 75% upon conversion within an 18-month tenure
EGM to approve the preferential issue scheduled for October 17, 2026
👀 What to Watch
Track voting outcomes at the upcoming EGM on October 17, 2026, and monitor the end-use of proceeds once disclosed (e.g. debt repayment or capex).
Choksi Labs Receives 4 USFDA Observations for Indore Central Laboratory
The USFDA conducted an inspection of Choksi Laboratories' central laboratory in Indore from August 17 to August 20, 2026. Upon conclusion of the inspection, the agency issued 4 observations to the company. Choksi Laboratories stated it is addressing the observations comprehensively and will submit its response within the stipulated timeframe.
Confidence: HIGH
What changedUSFDA completed its 4-day inspection of the Indore central lab and issued 4 regulatory observations.
Why it mattersRegulatory compliance is critical for testing and analytical laboratories servicing pharmaceutical and export clients; adverse escalation could impact client approvals.
Observations received: 4Inspection start date: August 17, 2026Inspection end date: August 20, 2026TTM Revenue: Rs 47 Cr
📅 Short termMarket focus will remain on the nature/severity of the 4 observations and the company's corrective and preventive action (CAPA) plan submission.
📈 Long termSuccessful resolution without escalation will maintain the facility's standing for US-regulated testing services; repeated non-compliance would risk regulatory escalation.
⚠ Risk flags
- Potential escalation to Warning Letter or Import Alert if USFDA finds remediation unsatisfactory
- High D/E of 1.20 and low net profit margins (~4.3%) provide limited cushion against compliance-related operational disruptions
Key Highlights
USFDA inspection conducted at Indore central laboratory between August 17, 2026, and August 20, 2026
Company received 4 observations at the conclusion of the inspection
Company committed to responding to the USFDA within the stipulated timeframe
Pertains to core testing infrastructure for a company with TTM revenue of Rs 47 Cr
👀 What to Watch
Track the company's response submission within the 15-day regulatory window and subsequent USFDA classification (e.g., NAI, VAI, or OAI) or EIR issuance.
Choksi Laboratories Approves Q1 FY27 Results; Auditor Issues Clean Review Report
Choksi Laboratories approved its unaudited financial results for the quarter ended June 30, 2026, on August 13, 2026. The statutory auditor, Prateek Jain & Co., issued a clean limited review report, confirming no material misstatements in the interim financials. The company, a micro-cap with a market capitalization of Rs 83 Cr, maintains a TTM revenue of Rs 46 Cr. Investors should note the company's debt levels, which at Rs 31 Cr, result in a debt-to-equity ratio of 1.20.
Confidence: MEDIUM
What changedThe company has completed its mandatory regulatory filing for the first quarter of the 2026-27 fiscal year.
Why it mattersThis filing provides the first operational update for the new fiscal year and confirms the company's adherence to Ind AS 34 reporting standards.
TTM Revenue: Rs 46 CrDebt: Rs 31 CrDebt-to-Equity: 1.20Market Cap: Rs 83 CrPromoter Holding: 31.48%
📅 Short termThe stock is likely to remain neutral in the short term as the announcement is a routine regulatory requirement without disclosed financial surprises in the text.
📈 Long termLimited structural impact; long-term performance depends on the company's ability to scale revenue beyond the current Rs 46 Cr TTM level and manage its debt-to-equity ratio.
⚠ Risk flags
- High Debt-to-Equity (1.20)
- Small-cap liquidity risk
- Relatively low promoter holding (31.48%)
Key Highlights
Board approved unaudited financial results for the quarter ended 30th June, 2026
Auditor Prateek Jain & Co. (FRN: 009494C) issued a clean Limited Review Report on 13th August, 2026
Company operates with a TTM revenue of Rs 46 Cr and a TTM PAT of Rs 2 Cr
Debt of Rs 31 Cr currently exceeds the company's net worth of Rs 26 Cr
Promoter holding remained stable at 31.48% as of the June 2026 quarter
👀 What to Watch
Monitor the detailed P&L statement for revenue growth trends relative to the Rs 11.24 Cr reported in the same quarter last year and check for any improvement in the 26.4% operating margin.
